Recombinant leukocyte A interferon as single agent therapy or in combination with cimetidine in patients with advanced colo-rectal carcinoma. A phase II investigation.
Recombinant leukocyte A interferon used as single agent therapy (7.5 X 10(6) units/m2 three times weekly intramuscularly) showed very limited clinical efficacy in patients with advanced colo-rectal carcinoma. No objective tumour regressions were documented in 15 evaluable patients, although three patients demonstrated a stable disease status after 12 weeks of treatment. Neither were any objective tumour regressions registered in 13 patients during subsequent combined therapy with Recombinant Leukocyte A Interferon and cimetidine (1 000 mg/day orally). Two of the 3 patients maintained their stable disease status. No change in natural killer (NK) cell activity or in antibody dependent cellular cytotoxicity (ADCC) of peripheral blood mononuclear cells was seen during the two treatment periods.
Flodgren
P
P
Hugander
A
A
Sjögren
H O
HO
D000368:Aged; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002927:Cimetidine / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D004274:DNA, Recombinant; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage* / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012004:Rectal Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D004274:DNA, Recombinant; D007370:Interferon Type I; D002927:Cimetidine